Question Bank › Richer on arrival: the business now flowing in c

Richer on arrival: the business now flowing in carries better economics than the blend the numbers show

Calls Tested
497
Answered YES
25
Hit Rate
5%
rare by design

Precipio, Inc. (PRPO) — this company's answers

NO on the Q3 2018 call 2018-11-19 D
The model's full reasoning — Q3 2018 call → NOWe need to determine if management conveys both halves: (1) incoming business is real and economically richer, and (2) reported numbers are a lagging blend and management says so. From the transcript: - Ilan discusses ICP, pathology services, IV-Cell, HemeScreen. He mentions Perkin Elmer partnership, expects 2019 revenues from ICP. But that's future. For pathology services, he says revenues from pathology services growing close to 50% from previous quarter, and expects to exceed $1 million per quarter by middle of 2019. That's growth but not necessarily better economics. - He mentions HemeScreen: "Since the launch of the test in our lab, only two weeks ago, we've already received numerous orders -- we've already run numerous orders received from physicians. We believe that given the market volume and revenue numbers of the current inferior test, that HemeScreen can generate revenues in excess of $1 million in 2019 and rapidly increase in the following years." That's future revenue, not current economics. - Carl Iberger: "From the productivity side, highlights come as Ilan has reviewed; from the R&D team, our sales organization and our diagnostic lab... Each group has done Yeoman's work during Q3 that will benefit upcoming financial performance." He mentions "we've seen steadily improved numbers on our new account closure rates." And "For 2018, pathology sales have accelerated quarter-over-quarter, we're pleased with this growth rate and we look for continued acceleration in Q4." Also "the lab management successfully expanded it's in-house molecular testing capabilities. This expansion will all but eliminate the need for very expensive outsourcing that we have incurring for the last 5 or 6 quarters, and it will have an immediate impact on lab cost of goods." That suggests that the new in-house testing reduces costs, so better economics. But is that "incoming business"? It's a capability improvement, not necessarily new business. However, it indicates that the reported numbers include costs of outsourcing that will be eliminated, so the reported numbers are a lagging blend? He says "immediate impact on lab cost of goods" - so that's a cost reduction, not necessarily richer incoming business.

← Back to the full PRPO analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management convey that the business NOW ARRIVING OR RAMPING at the company carries BETTER ECONOMICS than the blended results being reported — and that the reported numbers understate the company because they mix this richer incoming business with an older, lower-economics base or with temporary costs of scaling into it? Answer YES when management's own words convey, in whatever form fits the business, BOTH halves of ONE coherent story as a present-tense reality: (1) THE INCOMING BUSINESS IS REAL AND ECONOMICALLY RICHER. Management describes business that is actually arriving, ramping, or recently begun — real orders, customers, contracts, volumes, locations, products, or activity now flowing, not pipeline, hopes, or market opportunity — AND indicates that this newer business is economically better for the company than the base it is joining: better margins, better pricing or terms, lower cost to serve, faster payback, richer mix, better unit economics, or profitability the older business did not have. The comparison must be against the company's OWN existing or reported blend, expressed in whatever terms fit the industry, and grounded in what is actually being earned or booked now rather than in targets or models. (2) THE REPORTED NUMBERS ARE A LAGGING BLEND, AND MANAGEMENT SAYS SO. Management conveys, directly or plainly in substance, that the results being reported do not yet show these richer economics — because the new business is still a small share of the mix, because it began recently or mid-period, or because current results also carry identifiable costs of ramping, scaling, onboarding, or standing up that new business ahead of its revenue — so that as the mix naturally shifts and the ramp matures, results improve from what is already in motion rather than from anything still to be won. Answer NO if the improved economics are only targeted, planned, modeled, or hoped for rather than already being realized on real incoming business. NO if the better economics come chiefly from passing through cost inflation, favorable commodity or market prices the company passively receives, or one-time items. NO if the new business is described but management gives no indication it is economically better than the existing blend. NO if the richer business is already the dominant share of results, with no meaningful mix shift or ramp still ahead. NO if the company is chiefly explaining weakness, cutting costs on a shrinking business, or defending a struggling core. NO if the improvement depends mainly on market recovery, new demand not yet secured, or decisions not yet made. NO if the idea appears only in an analyst's question or model that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
ECPG Encore Capital Group, Inc. Q1 2024 2024-05-08 B
ASB Associated Banc-Corp Q1 2024 2024-04-25 A
HUYA HUYA Inc. Q4 2023 2024-03-19 C
GIII G-III Apparel Group, Ltd. Q4 2024 2024-03-14 C
AKYA Akoya Biosciences, Inc. Q2 2023 2023-08-07 C+
SPT Sprout Social, Inc. Q2 2023 2023-08-04 B+
CTO CTO Realty Growth, Inc. Q2 2023 2023-07-28 B
GVP GSE Systems, Inc. Q1 2023 2023-05-15 D
CARS Cars.com Inc. Q1 2023 2023-05-06 B
CRBG Corebridge Financial, Inc. Q4 2022 2023-02-22 B
TMCI Treace Medical Concepts, Inc. Q2 2022 2022-08-13 B+
FLR Fluor Corporation Q2 2022 2022-08-05 D
OGI OrganiGram Holdings Inc. Q3 2022 2022-07-14 B+
BFIN BankFinancial Corporation Q1 2022 2022-05-06 A
LC LendingClub Corporation Q4 2021 2022-01-26 A
EHTH eHealth, Inc. Q2 2021 2021-07-29 F
ADSK Autodesk, Inc. Q3 2019 2018-11-20 A
CUBI Customers Bancorp, Inc. Q3 2018 2018-10-26 C+
ESS Essex Property Trust, Inc. Q2 2018 2018-08-03 B+
IRT Independence Realty Trust, Inc. Q2 2018 2018-08-02 B
SATS EchoStar Corporation Q1 2018 2018-05-10 C+
ALLY Ally Financial Inc. Q1 2018 2018-04-26 B+
ATI Allegheny Technologies Incorporated Q1 2018 2018-04-24 B
FLEX Flex Ltd. Q1 2018 2017-07-28 F
DAN Dana Incorporated Q1 2017 2017-05-02 B

How the model reasoned

SPT · Q2 2023 → YESThe question is about whether management conveys that the incoming business has better economics than the blended results, and that reported numbers understate the company because they mix richer inco...YES Management describes real, incoming business (enterprise growth to 43% of ARR, Tagger acquisition, premium attach rates, mid-market unit economics) that is economically richer than the existing blend, with deprioritization of lower-quality low-end ARR.
AKYA · Q2 2023 → YESThe question is: Does management convey that the business NOW ARRIVING OR RAMPING at the company carries BETTER ECONOMICS than the blended results being reported — and that the reported numbers unders...
CRBG · Q4 2022 → YESThe question is: Does management convey that the business NOW ARRIVING OR RAMPING at the company carries BETTER ECONOMICS than the blended results being reported — and that the reported numbers unders...

More from the question bank

Doing it our way nowSelling out of one thing at a timeThe lull that never cameCrossed from claiming to demonstratingFixed price, unfixed volumeEverything is being bought forwardAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.